Deficiency of Alpha-1-Antitrypsin
We recommend
Characteristics of Patients with Alpha-1 Antitrypsin Deficiency – Two-Year Data from the EARCO Registry
The international registry of individuals with alpha-1 antitrypsin deficiency (AATD) named EARCO has collected data on 1,044 patients from 15 countries, including the Czech Republic, over its first 2 years of existence. In December 2022, the characteristics of patients enrolled from February 2020 to May 2022 were published. They provide information on the prevalence of AATD genotypes, their clinical phenotypes, factors associated with worsening lung function, and the impact of augmentation therapy.
To what extent does the delay between symptom onset and diagnosis of AATD affect patient survival?
The risk of chronic obstructive pulmonary disease (COPD) is increased, among other things, by a deficiency...
Augmentation Therapy of Bronchiectasis Due to AATD – Case Report
Alpha-1-antitrypsin deficiency (AATD) is a rare cause of bronchiectasis unrelated to cystic fibrosis....
Articles on this topic
Alpha-1 Antitrypsin Deficiency and Lung Disease in Patients with Primary Immunodeficiencies
Alpha-1 antitrypsin deficiency (AATD) plays a significant role in the pathogenesis of…
Alpha-1-Antitrypsin Deficiency and Its Association with Atopy in Asthmatics
Literature mentions the coincidence of asthma and alpha-1-antitrypsin deficiency, which is…
Antiviral and Anti-inflammatory Effects of Alpha-1-Antitrypsin in the Treatment of COVID-19
Human alpha-1-antitrypsin (AAT) is a circulating blood glycoprotein that has been used for…
European Registry of Patients with Alpha-1 Antitrypsin Deficiency EARCO Enrolls Patients
Insufficient identification of patients with alpha-1 antitrypsin deficiency (AATD) and a lack…
Can alpha-1-antitrypsin deficiency affect severity and higher mortality in COVID-19 patients?
Alpha-1-antitrypsin (AAT) deficiency is commonly found in the European population. The most…
Quantitative CT as a New Tool for Evaluating COPD in Alpha-1 Antitrypsin Deficiency
For such a rare hereditary disorder as alpha-1 antitrypsin deficiency (AATD), we have so far…
Long-term results of alpha-1-antitrypsin deficiency treatment – RAPID program
RAPID/RAPID Extension is the largest clinical program to date that has confirmed the benefit…
How Common is Alpha-1 Antitrypsin Deficiency?
What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are…
Impact of Alpha-1 Antitrypsin Deficiency on Quality of Life and Mental Health of Patients
The clinical manifestation of alpha-1 antitrypsin deficiency and its impact on quality of life…
Self-administration of alpha-1-antitrypsin can significantly improve patients' quality of life
Treatment of alpha-1 antitrypsin deficiency (AATD) requires lifetime administration of weekly…
Subscribe
Most read on this topic
Related topic
Interesting links
Most read on this topic
- Autoimmune Liver Diseases in Children. Part I
- Liver disease at alpha-1-antitrypsin deficiency
- Autoimmune liver diseases in children. Part II
- Rare diseases in the year 2019 – the Czech and international context
- Quantitative CT as a New Tool for Evaluating COPD in Alpha-1 Antitrypsin Deficiency
- Current (and Future) Possibilities for Diagnosing Alpha-1-Antitrypsin Deficiency
Related topic
Interesting links